# Optimisation of Hydromorphone - Naloxone Ratio for the Treatment of Pain

> **NCT00992576** · PHASE2,PHASE3 · COMPLETED · sponsor: **Mundipharma Research GmbH & Co KG** · enrollment: 600 (estimated)

## Conditions studied

- Constipation

## Interventions

- **DRUG:** Active Hydromorphone PR + Active Naloxone PR
- **DRUG:** Active Hydromorphone PR + Placebo Naloxone PR

## Key facts

- **NCT ID:** NCT00992576
- **Lead sponsor:** Mundipharma Research GmbH & Co KG
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-01
- **Primary completion:** 2011-11
- **Final completion:** 2012-01
- **Target enrollment:** 600 (ESTIMATED)
- **Last updated:** 2012-02-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00992576

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00992576, "Optimisation of Hydromorphone - Naloxone Ratio for the Treatment of Pain". Retrieved via AI Analytics 2026-07-13 from https://api.ai-analytics.org/clinical/NCT00992576. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*